HIGHLIGHTS
- who: License (https//creativecommons.org/licenses/by/ and collaborators from the INSERM, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Faculty of Medicine, University Paris-Saclay, Villejuif, France have published the article: Evaluating immune response in vitro a relevant microenvironment: high-throughput microfluidic model for clinical screening, in the Journal: (JOURNAL)
- what: The analysis was conducted on an array of the detected anchors using a protocol previously described . This study focused on autologous CD8+, an appropriate choice for ovary cancer cells.
- how: Because chemo and immunotherapy are not recommended in the first line for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.